Velcade(R) Plus Doxil(R) Improves Previously Treated Multiple Myeloma Patients
NORTH HOLLYWOOD, Calif., and CHICAGO, The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today said that data from a follow-up to a Phase 3 multi- national clinical trial shows the combination of DOXIL(R) with
VELCADE(R) improves the probability of survival by 41%. T...
Velcade (bortezomib) for Injection Based Induction Therapy
Delivered High Post-Transplant Complete Remission Rate, a Critical
Marker for Increased Overall Survival
- New Data from Phase III Intergroupe Francophone du Myelome (IFM)Trial Presented During IMW - CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today reported that new data werepresented on the comparative Phase III clinical trial evaluating a
VELCADE based therapy in newly diagnosed multiple myeloma (MM)patients. As induction therapy prior to stem...
Velcade (Bortezomib) for Injection Based Therapies Produced
Complete Remission Rates as High as 54 Percent in Patients With
Previously Treated Multiple Myeloma
- 100 percent of patients treated with
VELCADE, cyclophosphamide,and prednisone alive at one year - KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today reported on the presentation of resultsfrom clinical trials of
VELCADE based therapies that showed highcomplete remission / complete response(1) (CR) rates in previouslytreated multiple myeloma (MM) p...
Velcade (bortezomib) for Injection Based Therapies Achieved
Survival Rates as High as 100 Percent in Newly Diagnosed Multiple
Myeloma Patients
-- 100 percent response rate achieved with
VELCADE, lenalidomideand dexamethasone KOS, Greece, June 28 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. (Nasdaq: MLNM) today reported on thepresentation of results from four clinical trials of
VELCADE basedtherapies that showed consistently high survival and completeremission / complete response(1) (CR) rates in newly diag...
Velcade (bortezomib) for Injection Survival Data in Front-Line
Multiple Myeloma Patients to be Featured at 11th International
Myeloma Workshop
-- More than 70 abstracts highlight
VELCADE efficacy in broad rangeof patients and across continuum of care -- CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today announced that data for
VELCADE, the market leading therapy with unsurpassed single-agentefficacy for patients with previously treated multiple myeloma(MM), will be featured at the upco...
Study Shows Velcade Plus Doxil Improves Survival in Previously
Treated Patients With Multiple Myeloma
Data Presented at the ASCO Cancer Conference NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/-- The International Myeloma Foundation (IMF)-supporting researchand providing education, advocacy and support for myeloma patients,families, researchers and physicians-today said that data from afollow-up to a Phase 3 multi- national clinical trial shows thecombination of DOXIL(R)...
More>>